Futura Medical AI Stock Analysis
Futura Medical (GYX) AI Stock Analysis
Futura Medical
(Frankfurt:GYX)
No summary available
Futura Medical (GYX) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 878.87K
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.38
- Revenue Growth
- -71.75%
- EPS Growth
- 61.79%
- Country
- Germany
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Futura Medical Business Overview & Revenue Model
Company Description
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topic...
Futura Medical Earnings Call Summary
The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.
Futura Medical Peers Comparison
Overall Rating
GB:SBTX59Neutral
GB:POLB42Neutral
GB:AVCT40Underperform
GB:AREC33Underperform
GB:OPTI32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | GBP 12.31M | -26.39 | -5.25% | ― | 95.16% | 85.60% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | GBP 44.66M | -7.50 | -71.28% | ― | ― | 31.58% | |
| 40Underperform | GBP 287.20M | -6.47 | -1293.07% | ― | ― | ― | |
| 33Underperform | GBP 35.11M | 155.00 | 3.75% | ― | ― | ― | |
| 32Underperform | GBP 4.70M | -1.10 | -77.85% | ― | 11.90% | -2864.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:GYX | Futura Medical | 0.01 | 0.00 | 0.00% | |
| GB:AVCT | Avacta Group plc | 59.00 | -22.00 | -27.16% | |
| GB:OPTI | OptiBiotix Health | 4.55 | -3.70 | -44.85% | |
| GB:SBTX | SkinBioTherapeutics plc | 4.75 | -10.75 | -69.35% | |
| GB:POLB | Poolbeg Pharma Ltd. | 5.85 | 1.80 | 44.44% | |
| GB:AREC | Arecor Therapeutics PLC | 77.50 | 3.50 | 4.73% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
